1. Home
  2. ECPG vs PGEN Comparison

ECPG vs PGEN Comparison

Compare ECPG & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Encore Capital Group Inc

ECPG

Encore Capital Group Inc

N/A

Current Price

$103.24

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Logo Precigen Inc.

PGEN

Precigen Inc.

N/A

Current Price

$7.17

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ECPG
PGEN
Founded
1998
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.2B
IPO Year
1999
2013

Fundamental Metrics

Financial Performance
Metric
ECPG
PGEN
Price
$103.24
$7.17
Analyst Decision
Strong Buy
Buy
Analyst Count
3
5
Target Price
$77.33
$8.33
AVG Volume (30 Days)
332.9K
6.2M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
287.14
N/A
EPS
6.66
0.03
Revenue
$1,768,802,000.00
$230,981,000.00
Revenue This Year
$4.53
$1,115.92
Revenue Next Year
$4.76
$81.04
P/E Ratio
$15.20
$240.00
Revenue Growth
34.37
N/A
52 Week Low
$39.95
$2.99
52 Week High
$104.98
$7.50

Technical Indicators

Market Signals
Indicator
ECPG
PGEN
Relative Strength Index (RSI) 60.53 62.24
Support Level $77.69 $3.96
Resistance Level $104.98 $7.32
Average True Range (ATR) 4.04 0.43
MACD 0.09 0.01
Stochastic Oscillator 83.02 74.30

Price Performance

Historical Comparison
ECPG
PGEN

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: